Phesi Releases New Data Highlighting Impact from War in Ukraine
Almost 5% of global drugs trials are conducted in Ukraine and Russia and are now on hold.
New global data analysis from Phesi shows the extent of the impact from the war in Ukraine on clinical development. Phesi analyzed pivotal trials sponsored by pharmaceutical companies that represent the most critical global clinical development activities. The findings show that as of March 16, 2022, there were 65,593 recruiting investigator sites globally in this category. Of these, 2,911 (4.4%) sites were based in Ukraine and Russia, with the majority of pharmaceutical trials currently in Phase III.
Read more about this data release from Phesi
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Operational Strategies That Strengthened the NIMBLE Trial DesignSeptember 16th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
